Expanding Accessibility to CD19-CAR T Cells: Commercializing a "Boutique" Therapy

Mol Ther. 2017 Jan 4;25(1):8-9. doi: 10.1016/j.ymthe.2016.12.002. Epub 2017 Jan 4.

Authors

Premal Lulla¹, Carlos A Ramos²

Affiliations

¹ The Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA; Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: [email protected].
² The Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA; Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antigens, CD19*
Humans
Immunotherapy, Adoptive
Receptors, Antigen, T-Cell
T-Lymphocytes / immunology*

Substances

Antigens, CD19
Receptors, Antigen, T-Cell

Grants and funding